Business briefs: Teva, AbbVie, Novartis, Wockhardt

FDA grants Teva three years exclusivity to sell Plan B OTC for all ages; FDA gives Humira a thumbs-down for spondyloarthritis; a UK vaccine committee rejects Novartis' meningitis B shot; and Wockhardt gets a warning letter from FDA for its manufacturing practices at an Indian plant.

Business briefs: GSK, DOJ, Sanofi, Flashpoint Medica

GSK boots Shanghai R&D head over data fabrication; DOJ backs off of Plan B; Sanofi scores approval for new flu vaccine; laurels for Flashpoint Medica's Charlene Prounis

Email Newsletters